Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Hunan International Scientific and Technological Cooperation Base of Brain Tumor Research, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
J Transl Med. 2023 Jul 25;21(1):499. doi: 10.1186/s12967-023-04331-z.
Transcriptional programs are often dysregulated in cancers. A comprehensive investigation of potential regulons is critical to the understanding of tumorigeneses. We first constructed the regulatory networks from single-cell RNA sequencing data in human lung adenocarcinoma (LUAD). We next introduce LPRI (Lung Cancer Prognostic Regulon Index), a precision oncology framework to identify new biomarkers associated with prognosis by leveraging the single cell regulon atlas and bulk RNA sequencing or microarray datasets. We confirmed that LPRI could be a robust biomarker to guide prognosis stratification across lung adenocarcinoma cohorts. Finally, a multi-omics data analysis to characterize molecular alterations associated with LPRI was performed from The Cancer Genome Atlas (TCGA) dataset. Our study provides a comprehensive chart of regulons in LUAD. Additionally, LPRI will be used to help prognostic prediction and developing personalized treatment for future studies.
转录程序在癌症中经常失调。全面研究潜在的调节子对于理解肿瘤发生至关重要。我们首先从人类肺腺癌 (LUAD) 的单细胞 RNA 测序数据构建调控网络。接下来,我们引入 LPRI(肺癌预后调节子指数),这是一种精准肿瘤学框架,通过利用单细胞调节子图谱和批量 RNA 测序或微阵列数据集,识别与预后相关的新生物标志物。我们证实,LPRI 可以作为一个稳健的生物标志物,指导肺腺癌队列的预后分层。最后,我们从癌症基因组图谱 (TCGA) 数据集进行了多组学数据分析,以描述与 LPRI 相关的分子改变。我们的研究提供了 LUAD 中调节子的全面图谱。此外,LPRI 将用于帮助未来研究中的预后预测和制定个性化治疗方案。